Filippo Mulinacci
Chief Business Officer Araris Biotech AG
Dr. Filippo Mulinacci, MBA is Chief Business Officer at Araris Biotech AG, a wholly owned subsidiary of Taiho Pharmaceutical, leading business development and licensing strategy for the company’s ADC platforms. He brings over a decade of transactional experience in oncology and technology partnering. Previously, he was Oncology BD&L Manager at Basilea and spent nearly five years at Roche in global business development, identifying novel assets and negotiating collaborations across multiple therapeutic areas. Filippo began his career in research, holding positions at Merck-Serono where he focused on protein biochemistry and preformulation. He holds a MSc in Chemistry from the University of Turin, Italy, and a PhD in Pharmaceutical Sciences from the University of Geneva, Switzerland.
Seminars
- Introducing the site-specific conjugation platform process to understand the advantages of having multi payloads on native antibodies
- Demonstrating the efficacy of Dual ADCs in comparison to single-payload ADCs to overcome intra-tumoral heterogeneity
- Validating native antibody-like pharmacokinetics and safety profiles to showcase the benefits of hydrophilic peptide linkers in mitigating aggregation
As tumor heterogeneity and acquired resistance continue to limit the durability of single-payload ADCs, dual-payload
strategies are emerging as a powerful approach to deliver complementary mechanisms of action within a single, precisely engineered construct.
Join leading experts as they discuss how orthogonal chemistry, enzymatic precision, and innovative linker design can converge to create stable, scalable, and clinically translatable dual-payload ADC platforms by:
- Balancing combinatorial potency with molecular precision, examining how one-step multi-payload conjugation, glycan directed strategies, and orthogonal enzymatic chemistries can achieve controlled payload ratios and spatial placement to address tumor heterogeneity without compromising stability
- Redefining site-specific conjugation as the foundation for dual-payload success, debating how high-precision enzymatic platforms and EGCit-enabled linker systems can deliver homogeneous constructs with optimized DAR distribution, improved pharmacokinetics, and reduced off-target toxicity
- Designing linker architectures to strategically combat resistance, evaluating how innovative cleavable, traceless, or modality-specific linkers can coordinate sequential or complementary payload release, integrate novel payload classes, and maintain manufacturability while expanding the therapeutic index
